N/A N=68 Improving Vitamin D Status in Home-bound Elders
Vitamin D Deficiency · Accidental Falls
Primary: Change in 25-hydroxyvitamin D Levels Over 5 Months — 21.7; 0 ng/mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=62 Improving the Understanding of the Response to Vitamin D Supplementation
Vitamin D Deficiency
Primary: Change in Serum 25-hydroxy Vitamin D3 — 6.0; -0.8; 10.4; 0.3 ng/ml
Phase 3 N=265 Vitamin D Status of Pregnant Women and Their Children in Eau Claire, South Carolina
Vitamin D Deficiency · Pregnancy
Primary: 25-hydroxyvitamin D at Visit 7 — 36.7; 39.8 ng/mL
N/A N=81 Optimizing Vitamin D in the Elderly
Deficiency of Vitamin D3
Primary: Total 25-OH Vitamin D3 Level — 33; 34; 43; 61 ng/mL — p=<.0001
N/A N=225 Vitamin D and Vascular Health in Children
Obesity · Vitamin D Deficiency
Primary: Flow-mediated Dilation (FMD) Percentage — 7.61; 8.27; 7.31 percentage of baseline dilation — p=0.88
N/A N=30 Improving Vitamin D Status In Cystic Fibrosis
Cystic Fibrosis
Primary: 25-hydroxyvitamin D — 21.2; 24.4; 28.2 ng/mL
Phase 3 N=85 Effect of Vitamin D on Metabolic Profile in Overweight or Obese Women
Overweight · Obesity
Primary: Change in Body Fat Mass — -2.7; -0.4 kg — p=0.001
Phase 3 N=130 Vitamin D in Vulnerable Adults (VIVA-VA)
Frail Elderly · Vitamin d Deficiency
Primary: Change in Short Physical Performance Battery Test Score — 7.3; 7.0 units on a scale
Phase 1 N=157 Defining Vitamin D Insufficiency in School Age Children: A Randomized Placebo Controlled Trial of Vitamin D3
Healthy
Primary: Serum 25-hydroxyvitamin D — 26.7; 22.4 ng/mL — p=0.003
Phase 2 N=550 Topical Delivery of Vitamin D3 as Vitamin D Supplementation
Vitamin D Deficiency
Primary: Level of Serum 25 OHD Level Pre-treatment and Post Treatment — 12.03; 10.36; 37.17; 10.51 ng/mL — p=0.9
Phase 2 N=44 Vitamin D Dose Finding Study
HIV Infections · AIDS
Primary: Safety — 0; 0 participants
Phase 2 N=55 Supplementation With Cholecalciferol in Dialysis Patients
Chronic Kidney Disease
Primary: Change From Baseline in Interleukin-6 at 12 Weeks. — 9.0; 8.1; 9.6; 4.6 pg/mL
N/A N=43 Vitamin D Supplementation to Obese Chinese Males
Obesity · Insulin Resistance
Primary: Plasma 25-hydroxy Vitamin D (25(OH)D) Level (Nmol/L) — 116.7; 181.3; 46.1; 52.8 nmol/L
N/A N=96 Vitamin D Repletion in Coronary Artery Disease
Vitamin D Deficiency · Coronary Artery Disease · Endothelial Dysfunction
Primary: Endothelial Function — 0.13; -0.04 reactive hypermia index
Phase 4 N=183 Treatment Study of Vitamin D Deficiency in Adolescents
Vitamin D Deficiency
Primary: Change in 25(OH)D Serum Level After Treatment for Vitamin D Deficiency (Deficiency Defined as 25(OH)D <20 ng/dL) — 6.2; 24.9; 21 ng/mL
N/A N=40 Effect of Vitamin D Supplementation on Inflammation and Cardiometabolic Risk Factors in Obese Adolescents
Obesity
Primary: 25OH Vitamin D — 19.6; 25.8; 20.1; 24.6 ng/mL
Phase 2 N=85 Vitamin D HIV Study on Postmenopausal Women
HIV
Primary: Change in Bone Mineral Density (BMD) — 0.4; -0.8 percentage change
Phase 2 N=109 Correction of Vitamin D Levels and Its Effect on Insulin Resistance and Weight Gain in Obese Youth
Obesity · Insulin Resistance · Vitamin D Deficiency
Primary: Change in HOMA-IR — 0; -1.5; -1.7 HOMA-IR score
N/A N=37 Efficacy of Vitamin D Supplementation in Bariatric Surgery Patients
Obesity · Vitamin D Deficiency
Primary: Vitamin D Concentrations, Pre Operative and Post Bariatric Surgery Following 12 Weeks of Vitamin D Supplementation — 19.1; 27.2 ng/mL — p=< 0.001
Phase 2 N=51 Effect of Vitamin D3 Supplementation on Insulin Resistance and Cardiovascular Risk Factors in Obese Adolescents
Obesity
Primary: Change in Insulin Resistance After 12 Weeks of Vitamin D3 Supplementation — 0.01; -0.27 HOMA score — p=0.95
Phase 2 N=54 Vitamin D Levels in Stage IV Colorectal Cancer Patients
Colorectal Cancer
Primary: To Achieve Target Vitamin D Level — 41 participants
Phase 3 N=60 High Dose Preoperative Cholecalciferol Supplementation and Perioperative Vitamin D Status
Hypovitaminosis D
Primary: Percent (%) Change in 25(OH)D 5 Days Following Supplementation With 100,000 IU Cholecalciferol — 8; -2 percent change in 25(OH)D
N/A N=56 Vitamin D Supplementation in Healthy Adolescents
Vitamin D Supplementation
Primary: Baseline 25 Hydroxy Vitamin D (25OHD) Levels — 28.1; 29 ng/ml
N/A N=95 Vitamin D to Improve Outcomes by Leveraging Early Treatment: Long-term Brain Outcomes in Vitamin D Deficient Patients
Cognitive Decline
Primary: 12-month Cognition as Measured by the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) — 79.6; 82.1 units on a scale
Phase 4 N=230 Treatment of Vitamin D Insufficiency
Vitamin D Deficiency
Primary: Intestinal Calcium Absorption — 0.200; 0.217; 0.183; 0.206 Total Fractional Calcium Absorption
Phase 2 N=67 Rapid Normalization of Vitamin D in Critically Ill Children: A Phase II Dose Evaluation Randomized Controlled Trial
Hypovitaminosis D
Primary: Vitamin D Status — 81.6; 5.6 Percentage of participants in study arm
N/A N=200 Vitamin D Effects in Overweight Patients
Overweight · Obesity
Primary: Change in Body Weight From Baseline to 12 Months — -5.7; -6.4 kg
Phase 3 N=1,358 Vitamin D to Improve Outcomes by Leveraging Early Treatment
Acute Respiratory Distress Syndrome · Vitamin D Deficiency · Critical Illness
Primary: All-cause, All-location Mortality to Day 90 — 125; 109 Participants — p=0.26
N/A N=20 Vitamin D Supplementation in Kidney Disease
Renal Dialysis · Vitamin D Deficiency
Primary: Change in Hip Flexor Strength — 20.34; 6.83 percent change
N/A N=57 Pharmacokinetics of Vitamin D in Multiple Sclerosis and in Health
Multiple Sclerosis, Relapsing-remitting
Primary: Change in Mean Serum Level of 25-hydroxyvitamin D — 65.9; 82.4 nmol/L — p=0.001